Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROWN study: mesalazine withdrawal in Crohn's disease remission
NL-OMON36566Not yet recruiting
- Sponsor
- University of Michigan
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Salcrozine in Crohn's disease (2 arms), sponsored by University of Michigan. Primary endpoints: Clinical relapse during 18 months and Cost-effectiveness. Planned start Sep 2009; status: not yet recruiting.
02
Drugs
Salcrozine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON36566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36566.